Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for lung adenocarcinoma.
Adenocarcinoma of Lung
/ diagnosis
Antineoplastic Agents
/ pharmacology
Biomarkers, Tumor
Computational Biology
/ methods
Gene Expression Regulation, Neoplastic
/ drug effects
Gene Regulatory Networks
Humans
Kaplan-Meier Estimate
MicroRNAs
Molecular Sequence Annotation
Prognosis
RNA, Circular
RNA, Long Noncoding
RNA, Messenger
Transcriptome
Treatment Outcome
Circular RNA
Competing endogenous RNA
Drug sensitivity
Lung adenocarcinoma
Microarray expression
Overall survival
Prognostic biomarker
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
23 Jul 2021
23 Jul 2021
Historique:
received:
05
03
2021
accepted:
08
06
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
21
10
2021
Statut:
epublish
Résumé
More and more studies have proven that circular RNAs (circRNAs) play vital roles in cancer development via sponging miRNAs. However, the expression pattern of competing endogenous RNA (ceRNA) in lung adenocarcinoma (LUAD) remains largely unclear. The current study explored functional roles and the regulatory mechanisms of circRNA as ceRNAs in LUAD and their potential impact on LUAD patient prognosis. In this study, we systematically screened differential expression circRNAs (DEcircRNAs), miRNAs (DEmiRNAs) and mRNAs (DEGs) associated with LUAD. Then, DEcircRNAs, DEmiRNAs and DEGs were selected to construct a circRNA-miRNA-mRNA prognosis-related regulatory network based on interaction information from the ENCORI database. Subsequently, the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the genes in the network to predict the potential underlying mechanisms and functions of circRNAs in LUAD. In addition, Kaplan-Meier survival analysis was performed to evaluate clinical outcomes of LUAD patients, and drug sensitivity analysis was used to screen potential biomarkers for drug treatment of patients with LUAD. As a result, 10 circRNAs were aberrantly expressed in LUAD tissues. The ceRNA network was built, which included 3 DEcircRNAs, 6 DEmiRNAs and 157 DEGs. The DEGs in the ceRNA network of hsa_circ_0049271 enriched in biological processes of cell proliferation and the Jak-STAT signaling pathway. We also detected 7 mRNAs in the ceRNA network of hsa_circ_0049271 that were significantly associated with the overall survival of LUAD patients (P < 0.05). Importantly, four genes (PDGFB, CCND2, CTF1, IL7R) identified were strongly associated with STAT3 activation and drugs sensitivity in GDSC. In summary, a ceRNA network of hsa_circ_0049271 was successfully constructed, which including one circRNA, two miRNAs, and seven mRNAs. Seven mRNAs (PDGFB, TNFRSF19, CCND2, CTF1, IL11RA, IL7R and MAOA) were remarkably associated with the prognosis of LUAD patients. Among seven mRNA species, four genes (PDGFB, CCND2, CTF1, and IL7R) could be considered as drug targets in LUAD. Our research will provide new insights into the prognosis-related ceRNA network in LUAD.
Sections du résumé
BACKGROUND
BACKGROUND
More and more studies have proven that circular RNAs (circRNAs) play vital roles in cancer development via sponging miRNAs. However, the expression pattern of competing endogenous RNA (ceRNA) in lung adenocarcinoma (LUAD) remains largely unclear. The current study explored functional roles and the regulatory mechanisms of circRNA as ceRNAs in LUAD and their potential impact on LUAD patient prognosis.
METHODS
METHODS
In this study, we systematically screened differential expression circRNAs (DEcircRNAs), miRNAs (DEmiRNAs) and mRNAs (DEGs) associated with LUAD. Then, DEcircRNAs, DEmiRNAs and DEGs were selected to construct a circRNA-miRNA-mRNA prognosis-related regulatory network based on interaction information from the ENCORI database. Subsequently, the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the genes in the network to predict the potential underlying mechanisms and functions of circRNAs in LUAD. In addition, Kaplan-Meier survival analysis was performed to evaluate clinical outcomes of LUAD patients, and drug sensitivity analysis was used to screen potential biomarkers for drug treatment of patients with LUAD.
RESULTS
RESULTS
As a result, 10 circRNAs were aberrantly expressed in LUAD tissues. The ceRNA network was built, which included 3 DEcircRNAs, 6 DEmiRNAs and 157 DEGs. The DEGs in the ceRNA network of hsa_circ_0049271 enriched in biological processes of cell proliferation and the Jak-STAT signaling pathway. We also detected 7 mRNAs in the ceRNA network of hsa_circ_0049271 that were significantly associated with the overall survival of LUAD patients (P < 0.05). Importantly, four genes (PDGFB, CCND2, CTF1, IL7R) identified were strongly associated with STAT3 activation and drugs sensitivity in GDSC.
CONCLUSIONS
CONCLUSIONS
In summary, a ceRNA network of hsa_circ_0049271 was successfully constructed, which including one circRNA, two miRNAs, and seven mRNAs. Seven mRNAs (PDGFB, TNFRSF19, CCND2, CTF1, IL11RA, IL7R and MAOA) were remarkably associated with the prognosis of LUAD patients. Among seven mRNA species, four genes (PDGFB, CCND2, CTF1, and IL7R) could be considered as drug targets in LUAD. Our research will provide new insights into the prognosis-related ceRNA network in LUAD.
Identifiants
pubmed: 34301211
doi: 10.1186/s12885-021-08462-8
pii: 10.1186/s12885-021-08462-8
pmc: PMC8299662
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
MicroRNAs
0
RNA, Circular
0
RNA, Long Noncoding
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
849Informations de copyright
© 2021. The Author(s).
Références
RNA. 2014 Nov;20(11):1666-70
pubmed: 25234927
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Oncogene. 2018 Feb 1;37(5):555-565
pubmed: 28991235
Mol Cancer. 2019 Jan 9;18(1):6
pubmed: 30626395
Mol Cell. 2015 Jun 4;58(5):870-85
pubmed: 25921068
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Mol Cancer. 2018 Nov 19;17(1):160
pubmed: 30454010
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Cell Death Dis. 2020 Jan 16;11(1):32
pubmed: 31949130
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505
Cancer Cell Int. 2020 Jan 3;20:2
pubmed: 31911754
PLoS One. 2011;6(10):e26502
pubmed: 22046296
Cell Death Dis. 2018 Mar 16;9(4):417
pubmed: 29549306
Biochem Biophys Res Commun. 2018 Feb 19;496(4):1069-1075
pubmed: 29366790
Zhongguo Fei Ai Za Zhi. 2019 Jan 20;22(1):45-51
pubmed: 30674393
Cell Physiol Biochem. 2017;44(6):2138-2146
pubmed: 29241190
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancer Med. 2018 Jun;7(6):2783-2791
pubmed: 29722168
Br J Cancer. 2016 Dec 6;115(12):1513-1519
pubmed: 27855439
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Cancer Cell Int. 2020 May 19;20:173
pubmed: 32467668
Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8
pubmed: 17991681
Mol Cancer. 2019 Feb 4;18(1):20
pubmed: 30717751
Onco Targets Ther. 2020 Apr 08;13:2945-2955
pubmed: 32308427
Cell Mol Biol Lett. 2019 Dec 26;24:72
pubmed: 31889960
Bioinformatics. 2018 Jul 15;34(14):2515-2517
pubmed: 29509844
BMC Cancer. 2021 Mar 9;21(1):255
pubmed: 33750326
Cell. 2019 Feb 7;176(4):869-881.e13
pubmed: 30735636
Oncol Lett. 2018 Nov;16(5):5992-5996
pubmed: 30333870
Nucleic Acids Res. 2021 Jan 8;49(D1):D545-D551
pubmed: 33125081
Cell Prolif. 2019 Mar;52(2):e12548
pubmed: 30507050
Pharmacol Ther. 2018 Jul;187:31-44
pubmed: 29406246
Bioinformatics. 2018 Nov 1;34(21):3771-3772
pubmed: 29790900
Biochem Biophys Res Commun. 2019 Jan 1;508(1):37-45
pubmed: 30470570
Mol Genet Genomic Med. 2019 Dec;7(12):e991
pubmed: 31573758
J Thorac Oncol. 2013 Feb;8(2):250-3
pubmed: 23328551
Nature. 2012 Mar 28;483(7391):570-5
pubmed: 22460902
Mol Cell. 2018 Aug 2;71(3):428-442
pubmed: 30057200
Cell Mol Life Sci. 2018 Mar;75(6):1071-1098
pubmed: 29116363
Bratisl Lek Listy. 2019;66(11):819-826
pubmed: 31747761
Cancer Lett. 2017 Sep 10;403:305-317
pubmed: 28687357
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593